FDA Approval Alert: The Need-to-Know | Perioperative Nivolumab/Chemotherapy in Resectable NSCLC

In October 2024, the FDA approved nivolumab plus platinum-doublet chemotherapy for neoadjuvant treatment followed by single-agent nivolumab after surgery for patients with resectable non–small cell lung cancer with EGFR mutations or ALK rearrangements.

Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Article
Oct 3, 2024 3:29 PM
Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.